Intercept Pharmaceuticals Inc. (ICPT) announced its plans for an international Phase 3 trial of obeticholic acid Tuesday morning. The FXR agonist is a treatment for patients with non-cirrhotic nonalcoholic steatohepatitis with liver fibrosis.
Intercept Pharmaceuticals gapped open lower Tuesday and has dropped sharply in early trade. Shares are now down 31.48 at $282.50 on above average volume. The stock has fallen to a 1-week low.
For comments and feedback contact: editorial@rttnews.com
Business News